DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wv4c5j/companion) has announced the addition of the "2014 Report on the International Companion Diagnostics Market - Trends & Forecast to 2019" report to their offering.
The medications currently available commercially are becoming more and more personalized or targeted to specific patient populations. The development of a companion diagnostic along with the drug enables shortened drug development processes as its efficacy is already mapped by the patient outcomes. Hence, use of companion diagnostics increase the possibility of a drug attaining regulatory approval and also helps in evading long clinical trial design as only the targeted patient population needs to participate in the clinical trials. The escalating costs involved in drug discovery and development have created a need for development of cost effective solutions. Many pharmaceutical companies are now focusing on the co-development of companion diagnostics along with the drug.
Pharmaceutical manufacturers are focusing on development of tailor made therapies with the help of diagnostics manufacturers, in order to cater to the increasing demand for disease-specific therapies and defined target population. A large number of companion diagnostics are being developed in the field of oncology due to the continuous exploration of cancer-specific biomarkers, advanced technological platforms and large populations affected by different types of cancers.
North America dominated the global companion diagnostics market in 2012 with a revenue share of over 35%. Technological advances, increased healthcare awareness, large consumer base, and better affordability for expensive diagnostic procedures are the major factors responsible for the region's leadership position.
Key Topics Covered:
1 Introduction
2 Executive Summary
3 Market Overview
4 Companion Diagnostics Market, by Indication, 2011 - 2019 (USD Million)
5 Companion Diagnostics Market, by Geography, 2011 - 2019 (USD Million)
6 Competitive Landscape
7 Recommendations
8 Company Profiles
Companies Mentioned:
- Abbott Laboratories
- Agendia NV
- Agilent Technologies, Inc
- bioMérieux SA
- BioGenex Laboratories Inc
- GE Healthcare Ltd
- Genomic Health, Inc
- Life Technologies Corporation
- Qiagen NV
- Resonance Health Analysis Services Pty Ltd
- Roche Holdings AG
- Siemens Healthcare
For more information visit http://www.researchandmarkets.com/research/wv4c5j/companion
